Pretreatment with AMPT at doses which markedly altered the self-injection or amphetamine did not affect the self-injection of apomorphine. These data support the idea that the self-injection of apomorphine is produced via the direct activation of dopamine receptors rather than by the release of either norepinephrine or dopamine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0091-3057(76)90205-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Inhaled dry powder apomorphine (VR040) for 'off ' periods in Parkinson's disease: an in-clinic double-blind dose ranging study.
Acta Neurol Scand
September 2013
Department of Neurology, Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK.
Background: 'Off' periods increase as Parkinson's disease (PD) progresses and the benefits of standard therapy wane. Subcutaneous apomorphine rescues 'off' periods, but patient self-injection and adverse cutaneous effects are sometimes problematic.
Methods: We assessed safety, tolerability and efficacy of inhaled dry powder apomorphine (VR040) in a double-blind clinic-based Phase II study.
Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.
Arch Androl
April 2005
Reproductive Health Center, Kiawah Island, South Carolina 29455, USA.
Functional anatomy of the human penis involves various parameters: cavernous tissue, covering integument, prepuce foreskin, corpora cavernosa, corpus spongiosum, glans, facia, arterial supply, venous drainage, lymph drainage, musculature, and nerve supply. Several factors affect the expression/degree of erectile dysfunction (ED) endocrine profile, aging/senescence, demyelinating diseases, and surgery. Risk factors of ED are: age, vascular factors, metabolic diseases (diabetes mellitus), neurologic diseases, and HIV/AIDS.
View Article and Find Full Text PDF[Apomorphine for treatment of "off-periods" in Parkinson's disease].
Harefuah
November 1999
Dept. of Neurology, Rabin Medical Center, Petah Tikva.
After 3-5 years of continuous use of 1-dopa preparations for Parkinson's disease, 25%-50% of patients develop side-effects such as the "on-off" phenomenon and involuntary movements that markedly impair function. One cause of these manifestations is evidently a disturbance in the absorption of 1-dopa. We attempted to avoid this problem by using subcutaneous injections.
View Article and Find Full Text PDFA new era in the treatment of erectile dysfunction.
Am J Cardiol
September 1999
Male Clinic, Urology, Beverly Hills, California 90212, USA.
The recent introduction of sildenafil has revolutionized the treatment of erectile dysfunction (ED). The availability of sildenafil, the first effective oral agent for ED, has also expanded the field of sexual healthcare to include general and primary care practitioners and other nonurology specialists. A new process-of-care algorithm has been developed to facilitate the evaluation and treatment of ED in these nonurology settings.
View Article and Find Full Text PDFIntermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations.
Aust N Z J Med
June 1991
Monash Medical Centre, Melbourne, Vic., Australia.
Eight patients with severe Parkinsonian motor oscillations have been treated with the dopamine receptor agonist apomorphine by intermittent subcutaneous self-injection as an adjunct to oral anti-Parkinsonian medication. The dopamine receptor antagonist domperidone was also given by mouth to prevent nausea. Six patients remain on chronic treatment (mean period 6.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!